valproic acid has been researched along with Viremia in 2 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Viremia: The presence of viruses in the blood.
Excerpt | Relevance | Reference |
---|---|---|
" Given the limited evidence that resting CD4+ T cell infection (RCI) is affected by the histone deacetylase (HDAC) inhibitor valproic acid (VPA), we measured the stability of RCI and residual viremia in patients who added VPA with or without raltegravir (RAL), or enfuvirtide (ENF) with or without VPA, to standard ART." | 9.14 | Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. ( Archin, NM; Bosch, RJ; Cheema, M; Coffin, JM; Cohen, M; Eron, J; Margolis, DM; Parker, D; Wiegand, A, 2010) |
" Given the limited evidence that resting CD4+ T cell infection (RCI) is affected by the histone deacetylase (HDAC) inhibitor valproic acid (VPA), we measured the stability of RCI and residual viremia in patients who added VPA with or without raltegravir (RAL), or enfuvirtide (ENF) with or without VPA, to standard ART." | 5.14 | Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. ( Archin, NM; Bosch, RJ; Cheema, M; Coffin, JM; Cohen, M; Eron, J; Margolis, DM; Parker, D; Wiegand, A, 2010) |
"Low-level viremia was quantitated by single copy plasma HIV RNA assay." | 1.35 | Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. ( Archin, NM; Bandarenko, N; Bosch, RJ; Coffin, JM; Eron, JJ; Hartmann-Duff, A; Landay, AL; Margolis, DM; Martinson, JA; Palmer, S; Schmitz, JL; Wiegand, A, 2008) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Archin, NM | 2 |
Eron, JJ | 1 |
Palmer, S | 1 |
Hartmann-Duff, A | 1 |
Martinson, JA | 1 |
Wiegand, A | 2 |
Bandarenko, N | 1 |
Schmitz, JL | 1 |
Bosch, RJ | 2 |
Landay, AL | 1 |
Coffin, JM | 2 |
Margolis, DM | 2 |
Cheema, M | 1 |
Parker, D | 1 |
Eron, J | 1 |
Cohen, M | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
IGHID 1309 -A Phase I Study to Evaluate the Kinetics of the Immunologic Response and Virologic Impact of AGS-004 in HIV-Infected Individuals Suppressed on Antiretroviral Therapy Initiated During Acute and Chronic HIV Infection[NCT02042248] | Phase 1 | 6 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
IGHID 1320 - A Phase I Study to Evaluate the Safety, Immunologic, and Virologic Responses of HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) as a Therapeutic Strategy in HIV-Infected Individuals Started on Antiretroviral Therapy During Acute and Chr[NCT02208167] | Phase 1 | 6 participants (Actual) | Interventional | 2015-04-07 | Completed | ||
IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)[NCT02707900] | Phase 1 | 6 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to Manufacturing of the AGS-004 HIV vaccine by Argos could no longer be provided.) | ||
IGHID 11417 - The Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection: Impact on the Latent HIV Reservoir and Long-Term Immunologic Effect[NCT02384395] | 40 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
Research In Viral Eradication of HIV Reservoirs[NCT02336074] | Phase 2 | 60 participants (Actual) | Interventional | 2015-11-27 | Completed | ||
10493 - MK-0518 Intensification and HDAC Inhibition in Depletion of Resting CD4+ T Cell HIV Infection[NCT00614458] | Phase 2 | 6 participants (Actual) | Interventional | 2007-04-30 | Terminated (stopped due to Due to insufficient funds) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
(NCT02384395)
Timeframe: Baseline, Week 24
Intervention | copies/mL (Median) |
---|---|
DTG/3TC/ABC FDC | -590211 |
Sign/symptom, lab toxicity, or clinical events, or Grade 3 or higher AE that is definitely, probably, or possibly related to study treatment (NCT02384395)
Timeframe: Baseline through Week 96
Intervention | Participants (Count of Participants) |
---|---|
DTG/3TC/ABC FDC | 1 |
Total number of participants on study at Week 24 with an HIV-1 RNA level less than 200 copies/mL (NCT02384395)
Timeframe: Week 24
Intervention | Participants (Count of Participants) |
---|---|
DTG/3TC/ABC FDC | 34 |
Proportion of participants completing Week 48 with an HIV-1 RNA level less than 50 copies/mL (NCT02384395)
Timeframe: Week 48
Intervention | proportion of participants (Number) |
---|---|
DTG/3TC/ABC FDC | 0.88 |
Histone H4 acetylation using a H4K5/8/12/16 immunoassay with thawed PBMC derived cell lysates added to an ELISA using anti-H4 monoclonal antibody (NCT02336074)
Timeframe: 12 weeks
Intervention | Fold increase pre to post vorinostat (Mean) |
---|---|
Intervention (Arm B - ART + Vaccines + Vorinostat) | 3.19 |
Number of Participants with undetectable quantitative viral outgrowth (NCT02336074)
Timeframe: At week 16
Intervention | Participants with undetectable outgrowth (Number) |
---|---|
Control (Arm A - ART Only) | 12 |
Intervention (Arm B - ART + Vaccines + Vorinostat) | 6 |
The average of two measures taken at post-randomisation week 16 and 18 (NCT02336074)
Timeframe: Averaged across post-randomisation week 16 and 18
Intervention | HIV-DNA copies/mill CD4+ T cells (log10) (Mean) |
---|---|
Control (Arm A - ART Only) | 2.95 |
Intervention (Arm B - ART + Vaccines + Vorinostat) | 3.06 |
"CD8+ T cell antiviral suppressive activity was expressed as percentage elimination and determined as follows: [(fraction of p24+ cells in CD4+ T cells cultured alone) - (fraction of p24 + in CD4+ T cells cultured with CD8+ cells)]/(fraction of p24+ cells in CD4+ T cells cultured alone) × 100.~Viral inhibition Assay" (NCT02336074)
Timeframe: 12 weeks
Intervention | Percentage elimination (Mean) |
---|---|
Control (Arm A - ART Only) | -18.25 |
Intervention (Arm B - ART + Vaccines + Vorinostat) | 1.50 |
Percentage of CD8+ CD107a+ IFNγ+ T cells , assessed using an optimized and qualified flow cytometry panel. (NCT02336074)
Timeframe: 12 weeks
Intervention | % cells CD8+ CD107a+ IFNγ+ (Median) | |
---|---|---|
Post randomisation week 9 | Post randomisation week 12 | |
Control (Arm A - ART Only) | 0.052 | 0.062 |
Intervention (Arm B - ART + Vaccines + Vorinostat) | 0.194 | 0.263 |
Percentage of CD4+ CD154+ IFNγ+ T cells , assessed using an optimized and qualified flow cytometry panel. (NCT02336074)
Timeframe: 12 weeks
Intervention | % cells CD4+ CD154+ IFNγ+ (Median) | |
---|---|---|
Post randomisation week 9 | Post randomisation week 12 | |
Control (Arm A - ART Only) | 0.006 | 0.006 |
Intervention (Arm B - ART + Vaccines + Vorinostat) | 0.097 | 0.109 |
A change in infected cells from prior to the initiation of VPA and MK0518 to after 20 weeks of treatment. (NCT00614458)
Timeframe: 20 weeks
Intervention | infected cells /million cells (Median) |
---|---|
Effect on Latent HIV of Adding Raltegravir and VPA to ART | 0.390 |
1 trial available for valproic acid and Viremia
Article | Year |
---|---|
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio | 2010 |
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio | 2010 |
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio | 2010 |
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio | 2010 |
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio | 2010 |
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio | 2010 |
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio | 2010 |
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio | 2010 |
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio | 2010 |
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio | 2010 |
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio | 2010 |
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio | 2010 |
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio | 2010 |
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio | 2010 |
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio | 2010 |
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Administratio | 2010 |
1 other study available for valproic acid and Viremia
Article | Year |
---|---|
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb | 2008 |
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb | 2008 |
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb | 2008 |
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb | 2008 |
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb | 2008 |
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb | 2008 |
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb | 2008 |
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb | 2008 |
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb | 2008 |
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb | 2008 |
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb | 2008 |
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb | 2008 |
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb | 2008 |
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb | 2008 |
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb | 2008 |
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
Topics: Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Drug Therapy, Comb | 2008 |